Cargando…
Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
BACKGROUND: The present study compared the effects of antifibrotic medications, pirfenidone, and nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF). METHODS: A stable animal model was established via an intratracheal injection...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702727/ https://www.ncbi.nlm.nih.gov/pubmed/33256831 http://dx.doi.org/10.1186/s13287-020-02012-y |
_version_ | 1783616602539819008 |
---|---|
author | Chu, Kuo-An Yeh, Chang-Ching Kuo, Fu-Hsien Lin, Wen-Ren Hsu, Chien-Wei Chen, Tien-Hua Fu, Yu-Show |
author_facet | Chu, Kuo-An Yeh, Chang-Ching Kuo, Fu-Hsien Lin, Wen-Ren Hsu, Chien-Wei Chen, Tien-Hua Fu, Yu-Show |
author_sort | Chu, Kuo-An |
collection | PubMed |
description | BACKGROUND: The present study compared the effects of antifibrotic medications, pirfenidone, and nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF). METHODS: A stable animal model was established via an intratracheal injection of 5 mg bleomycin (BLM). One single transplantation of 2.5× 10(7) HUMSCs or initiation of daily oral nintedanib/pirfenidone administration was performed on day 21 following BLM damage. RESULTS: Pulmonary function examination revealed that BLM rats exhibited a significant decrease in blood oxygen saturation and an increase in respiratory rates. While no significant improvements were found in BLM rats receiving nintedanib or pirfenidone, those who transplanted with HUMSCs showed a statistical amelioration in blood oxygen saturation and significant alleviation in respiratory rates. Quantification results revealed that a significant reduction in alveolar space and marked increases in substantial cell infiltration and collagen deposition in the left lungs of BLM rats. No significant alteration was observed in BLM rats administered nintedanib or pirfenidone. However, BLM rats transplanted with HUMSCs had a significant recovery in alveolar space and noticeable decreases in cell infiltration and collagen deposition. The inflammatory cell numbers in the bronchoalveolar lavage was increased in the BLM group. While the rats treated with nintedanib or pirfenidone had a lower cell number than the BLM group, a higher cell number was found as compared with the Normal group. In rats transplanted with HUMSCs, the cell number did not differ from the Normal group. CONCLUSIONS: Transplantation of HUMSCs could effectively treat PF as opposed to the administration of anti-fibrotic drugs with nintedanib or pirfenidone with a significant better result in lung volume, pathological changes, lung function, and blood oxygen saturation. |
format | Online Article Text |
id | pubmed-7702727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77027272020-12-01 Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly Chu, Kuo-An Yeh, Chang-Ching Kuo, Fu-Hsien Lin, Wen-Ren Hsu, Chien-Wei Chen, Tien-Hua Fu, Yu-Show Stem Cell Res Ther Research BACKGROUND: The present study compared the effects of antifibrotic medications, pirfenidone, and nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF). METHODS: A stable animal model was established via an intratracheal injection of 5 mg bleomycin (BLM). One single transplantation of 2.5× 10(7) HUMSCs or initiation of daily oral nintedanib/pirfenidone administration was performed on day 21 following BLM damage. RESULTS: Pulmonary function examination revealed that BLM rats exhibited a significant decrease in blood oxygen saturation and an increase in respiratory rates. While no significant improvements were found in BLM rats receiving nintedanib or pirfenidone, those who transplanted with HUMSCs showed a statistical amelioration in blood oxygen saturation and significant alleviation in respiratory rates. Quantification results revealed that a significant reduction in alveolar space and marked increases in substantial cell infiltration and collagen deposition in the left lungs of BLM rats. No significant alteration was observed in BLM rats administered nintedanib or pirfenidone. However, BLM rats transplanted with HUMSCs had a significant recovery in alveolar space and noticeable decreases in cell infiltration and collagen deposition. The inflammatory cell numbers in the bronchoalveolar lavage was increased in the BLM group. While the rats treated with nintedanib or pirfenidone had a lower cell number than the BLM group, a higher cell number was found as compared with the Normal group. In rats transplanted with HUMSCs, the cell number did not differ from the Normal group. CONCLUSIONS: Transplantation of HUMSCs could effectively treat PF as opposed to the administration of anti-fibrotic drugs with nintedanib or pirfenidone with a significant better result in lung volume, pathological changes, lung function, and blood oxygen saturation. BioMed Central 2020-11-30 /pmc/articles/PMC7702727/ /pubmed/33256831 http://dx.doi.org/10.1186/s13287-020-02012-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chu, Kuo-An Yeh, Chang-Ching Kuo, Fu-Hsien Lin, Wen-Ren Hsu, Chien-Wei Chen, Tien-Hua Fu, Yu-Show Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly |
title | Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly |
title_full | Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly |
title_fullStr | Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly |
title_full_unstemmed | Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly |
title_short | Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly |
title_sort | comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from wharton’s jelly |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702727/ https://www.ncbi.nlm.nih.gov/pubmed/33256831 http://dx.doi.org/10.1186/s13287-020-02012-y |
work_keys_str_mv | AT chukuoan comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly AT yehchangching comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly AT kuofuhsien comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly AT linwenren comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly AT hsuchienwei comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly AT chentienhua comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly AT fuyushow comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly |